Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months.
Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months.
复制标题
DOI:
10.1007/s10067-021-05942-x
复制
发表时间:
2022-01
影响因子:
3.4
通讯作者:
Kardeş S
中科院分区:
文献类型:
--
作者:
Karaarslan F;Güneri FD;Kardeş S
To document the detailed characteristics including severity, type, and locations of rheumatic and musculoskeletal symptoms along with other COVID-19 persistent symptoms in hospitalized COVID-19 survivors at 3 and 6 months. In this extension cohort study, two telephone surveys at 3 and 6 months following the hospitalization were carried out. In these telephone surveys, participants were asked regarding their symptoms through a previously designed standard questionnaire. At 3 months, 89.0% of survivors had at least one symptom, 74.6% had at least one rheumatic and musculoskeletal symptom, and 82.1% had at least one other COVID-19 symptom. At 6 months, 59.6% of survivors had at least one symptom, 43.2% had at least one rheumatic and musculoskeletal symptom, and 51.2% had at least one other COVID-19 symptom. Regarding the rheumatic and musculoskeletal symptoms, 31.6% had fatigue, 18.6% had joint pain, and 15.1% had myalgia; and regarding the other-COVID-19-symptoms, 25.3% had dyspnea, 20.0% had hair loss, and 17.2% sweat at 6 months. In an adjusted model, female patients were more likely to have fatigue (OR: 1.99, 95% CI: 1.18–3.34), myalgia (3.00, 1.51–5.98), and joint pain (3.39, 1.78–6.50) at 6 months. Approximately 3 in 5 patients had at least one symptom with ≈2 in 5 patients had at least one rheumatic and musculoskeletal symptom. Fatigue, joint pain, and myalgia were the most frequent rheumatic and musculoskeletal symptoms. Joint pain and myalgia were mostly widespread. This information guide rheumatologists to understand the nature and features of persistent rheumatic and musculoskeletal symptoms in hospitalized COVID-19 survivors and may contribute to better management of these individuals.
登录
查看更多内容
影响因子:
4
作者:
Karaarslan F;Demircioğlu Güneri F;Kardeş S
通讯作者:
Kardeş S
DOI:
10.1016/j.cmi.2021.05.033
发表时间:
2021-10
期刊:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子:
--
作者:
Peghin M;Palese A;Venturini M;De Martino M;Gerussi V;Graziano E;Bontempo G;Marrella F;Tommasini A;Fabris M;Curcio F;Isola M;Tascini C
通讯作者:
Tascini C
影响因子:
9.1
作者:
Oronsky B;Larson C;Hammond TC;Oronsky A;Kesari S;Lybeck M;Reid TR
通讯作者:
Reid TR
影响因子:
7.5
作者:
Fortini A;Torrigiani A;Sbaragli S;Lo Forte A;Crociani A;Cecchini P;Innocenti Bruni G;Faraone A
通讯作者:
Faraone A
影响因子:
7.4
作者:
Van Herck M;Goërtz YMJ;Houben-Wilke S;Machado FVC;Meys R;Delbressine JM;Vaes AW;Burtin C;Posthuma R;Franssen FME;Hajian B;Vijlbrief H;Spies Y;van 't Hul AJ;Janssen DJA;Spruit MA
通讯作者:
Spruit MA